Lipitor - ladder

Help provide your high-risk patients with strong CV support

Lipitor puts the power to help change the outcome of CVD in your hands by reducing the risk of MI and Stroke.

Lipitor is the only potent mean LDL-C reductions >50%, and, unlike Crestor, has CV outcomes indications for high-risk patients with CHD or patients with type 2 diabetes and risk factor.

Available as a generic after 11/30/2011–now is the time to prescribe Lipitor for many of your high-risk patients

Powered by outcomes

---

Campaign files

---

Brand name: Lipitor
Generic name/category: Atorvastatin, Statin, Cardiovascular
Company: Pfizer
Country/Market: USA, North America
Indication(s)/Category: high cholesterol, reduce the risk of myocardial infarction, stroke, revascularization procedures, CHF and angina
Target: Healthcare Professionals (HCP)
Tagline: Powered by outcomes
Medium: Print ad
Size/duration: Single-page
Publication/Aired: JAMA - November 10, 2010

To see all of this brand's ads on AdPharm, [url=https://adpharm.net/thumbnails.php?search=Lipitor"> Campaign files

From Wikipedia:
Atorvastatin (INN) (Lipitor, Pfizer), is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms.

Atorvastatin inhibits HMG-CoA reductase, the rate-determining enzyme located in hepatic tissue that produces mevalonate, a small molecule used in the synthesis of cholesterol and other mevalonate derivatives. This lowers the amount of cholesterol produced which in turn lowers the total amount of LDL cholesterol. Atorvastatin was first synthesized in 1985 by Bruce Roth while working at Parke-Davis Warner-Lambert Company (now Pfizer). With 2008 sales of US$12.4 billion, Lipitor is the top-sellinged pharmaceutical in the world. US patent protection is scheduled to expire in June 2011. However, Pfizer made an agreement with Ranbaxy Laboratories to delay the generic launch in the US until November 2011.

More on Wikipedia